A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors
This study tests a new experimental medication called EIS-12656, both on its own and mixed with other targeted cancer drugs, for people with advanced solid tumors. Researchers want to find the safest dose and see if this new treatment can help shrink tumors that have specific genetic changes.
You might be able to join if you have advanced cancer that has grown or spread, and your tumor has specific genetic flaws related to how cells repair DNA. Participants also need to have healthy organ function and be able to travel to the study location.
You will receive the study medication, either by itself or along with another approved cancer treatment, while doctors closely monitor your health and safety. You will undergo regular check-ups and imaging scans to see how your body and your tumor respond to the treatment.
The study is currently actively recruiting participants in Houston, Texas, United States. More locations may become available in the future.
- 1Tests a new experimental drug called EIS-12656 for advanced solid tumors
- 2Looks for the right dose and checks for safety and effectiveness
- 3Requires specific genetic changes in your tumor related to DNA repair
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.